Candel Therapeutics
CADL
12 hedge funds and large institutions have $52.9M invested in Candel Therapeutics in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
17.02% more ownership
Funds ownership: 0% → 17.02% (+17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$9.33M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.77M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$829K |
| 5 |
CCM
CAAS Capital Management
New York
|
+$415K |
Top Sellers
CADL Hedge Fund Activity: Q3 2021 in Review
12 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q3 2021, worth a combined $52.9M.
Buyers outnumbered sellers: 12 funds opened new CADL positions and 0 closed out — a net gain of 12 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $20.7M.
- 12 institutional investors held Candel Therapeutics (CADL) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $52.9M of Candel Therapeutics stock for Q3 2021.
- 12 funds opened new Candel Therapeutics positions in Q3 2021 and 0 closed out, a net change of +12 holders.
- The largest Candel Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $20.7M added.
Based on aggregated 13F filings for Q3 2021.